EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

HPDL Variant Type Correlates With Clinical Disease Onset and Severity

Eun Hye Lee iD, Olivia Kim-Mcmanus iD, Jennifer H Yang, Richard Haas, Maha S Zaki, Ghada M H Abdel-Salam, Yuji Nakamura, Mohamed S Abdel-Hamind, Darius Ebrahimi-Fakhari iD, Julian E Alecu, Nicola Brunetti-Pierri, Varunvenkat M Srinivasan und 8 weitere

Annals of Clinical and Translational Neurology · 2025

DOI: 10.1002/acn3.70047 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Annals of Clinical and Translational Neurology, 2025. Verfasst von Eun Hye Lee und 19 weiteren Autor:innen. Beteiligte Einrichtung: Rady Children's Institute for Genomic Medicine, San Diego, California, USA. Hauptthemen laut MEDLINE: Iron-Binding Proteins, Mitochondrial Encephalomyopathies. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Recently, a mitochondrial encephalopathy due to biallelic HPDL variants was described, associated with a broad range of clinical manifestations ranging from severe, infantile‐onset neurodegeneration to adolescence‐onset hereditary spastic paraplegia. HPDL converts 4‐hydroxyphenylpyruvate acid (4‐HPPA) into 4‐hydroxymandelate (4‐HMA), necessary for the synthesis of the mitochondrial electron transporter CoQ10. This suggests a possible bypass of the metabolic block by 4‐HMA treatment; however, genotype–phenotype correlations are lacking.

Methods

We established an HPDL Patient Registry to prepare for a future clinical trial. Here we report the clinical features of 13 enrolled participants and compare them with 86 previously reported patients. We establish three major clinical classes: severe, intermediate, and mild, presenting onset in early infancy, childhood, and adolescence, respectively. The biallelic genotypes were classified into truncating/truncating, truncating/missense, and missense/missense variants, mapped onto the predicted 3D protein structure, and correlated with severity.

Results

Patients with biallelic truncating variants presented with severe phenotypes and earlier ages of onset. Missense variants were often associated with milder phenotypes, except those with variants predominantly located in or near the VOC2 domain containing iron‐binding sites or the C‐terminus, which had more severe phenotypes. In addition, p.Met1? variants were also correlated with more severe phenotypes.

Interpretation

This study demonstrates the correlation of age of onset and disease severity with genotype for HPDL‐ related conditions. Patients with truncating variants and specific missense variants correlated with severe, early‐onset features, whereas the presence of at least one missense variant located outside of the iron‐binding sites correlated with milder presentations. Trial Registration Clinicaltrials.gov HPDL registry: https://clinicaltrials.gov/study/NCT05848271

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Iron-Binding ProteinsMitochondrial EncephalomyopathiesAdolescentChildChild, PreschoolFemaleHumansInfantMaleAge of OnsetGenetic Association StudiesPhenotypeRegistriesSeverity of Illness Index

Stichwörter der Autor:innen

4‐hydroxyphenylpyruvate dioxygenase‐like proteinHPDLencephalopathyhereditary spastic paraplegiamitochondria

Substanzen

HPDL protein, humanIron-Binding Proteins

Autor:innen und Institutionen

  • Rady Children's Institute for Genomic Medicine, San Diego, California, USA.
  • Department of Pediatrics, College of Medicine, Kyung Hee University, Seoul, Korea.
  • Department of Neurosciences and Pediatrics, University of California, San Diego, California, USA.
  • Human Genetics and Genome Research Division, Clinical Genetics Department, National Research Centre, Cairo, Egypt.
  • Human Genetics and Genome Research Division, Medical Molecular Genetic Department, National Research Centre, Cairo, Egypt.
  • Department of Neurology, F.M. Kirby Neurobiology Center, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Eun Hye Lee, Olivia Kim-Mcmanus, Darius Ebrahimi-Fakhari, Joseph G Gleeson

Förderung

  • NINDS NIH HHS

Zitieren

APA

Lee, E. H., Kim-Mcmanus, O., Yang, J. H., Haas, R., Zaki, M. S., Abdel-Salam, G. M. H., Nakamura, Y., Abdel-Hamind, M. S., Ebrahimi-Fakhari, D., Alecu, J. E., Brunetti-Pierri, N., Srinivasan, V. M., Gowda, V. K., Gross, S., Alanay, Y., Najarzadeh Totbati, P., Yadavilli, M., Friedman, L., Ojeda, N. M., & Gleeson, J. G. (2025). HPDL Variant Type Correlates With Clinical Disease Onset and Severity. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70047

Vancouver

Lee EH, Kim-Mcmanus O, Yang JH, Haas R, Zaki MS, Abdel-Salam GMH, et al. HPDL Variant Type Correlates With Clinical Disease Onset and Severity. Annals of Clinical and Translational Neurology. 2025. doi:10.1002/acn3.70047

BibTeX
@article{Lee2025,
  author = {Lee, Eun Hye and Kim-Mcmanus, Olivia and Yang, Jennifer H and Haas, Richard and Zaki, Maha S and Abdel-Salam, Ghada M H and Nakamura, Yuji and Abdel-Hamind, Mohamed S and Ebrahimi-Fakhari, Darius and Alecu, Julian E and Brunetti-Pierri, Nicola and Srinivasan, Varunvenkat M and Gowda, Vykuntaraju K and Gross, Stephanie and Alanay, Yasemin and Najarzadeh Totbati, Paria and Yadavilli, Manya and Friedman, Liana and Ojeda, Naomi Meave and Gleeson, Joseph G},
  title = {HPDL Variant Type Correlates With Clinical Disease Onset and Severity},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2025},
  doi = {10.1002/acn3.70047}
}
Kostenlos starten →